XOMA Royalty (XOMA) Cash from Financing Activities (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Cash from Financing Activities came in at -$7.6 million in Q1 2026, down 10.82% year-on-year from -$8.6 million in Q1 2025, and up 28.52% quarter-over-quarter from -$10.7 million in Q4 2025.
XOMA Royalty (XOMA) Cash from Financing Activities (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Cash from Financing Activities across 17 years of filings, most recently posting -$7.6 million for Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at -$7.6 million, down 10.82% year-over-year; the trailing twelve-month figure through Mar 2026 was -$27.2 million (down 108.26% YoY), and the FY2025 annual result was -$26.5 million, down 137.83% from the prior year.
- Cash from Financing Activities came in at -$7.6 million for Q1 2026 at XOMA Royalty, up from -$10.7 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $124.5 million in Q4 2023 to a low of -$10.7 million in Q4 2025.
- The 5-year median for Cash from Financing Activities is -$1.4 million (2023), against an average of $4.2 million.
- Across the five-year window, Cash from Financing Activities jumped 9517.1% in 2023 and plunged 902.72% in 2025, its largest moves.
- XOMA Royalty's Cash from Financing Activities stood at -$1.3 million in 2022, then surged by 9517.1% to $124.5 million in 2023, then sank by 100.86% to -$1.1 million in 2024, then slumped by 902.72% to -$10.7 million in 2025, then increased by 28.52% to -$7.6 million in 2026.
- The last three Cash from Financing Activities figures came in at -$7.6 million (Q1 2026), -$10.7 million (Q4 2025), and -$5.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 53,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 85,464.43 |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | -7.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.64 Mn |
| Mar 31, 2026 | -7.64 Mn |
| Dec 31, 2025 | -10.69 Mn |
| Dec 31, 2025 | -10.69 Mn |
| Sep 30, 2025 | -5.85 Mn |
| Sep 30, 2025 | -5.85 Mn |
| Jun 30, 2025 | -3.03 Mn |
| Jun 30, 2025 | -3.03 Mn |
| Mar 31, 2025 | -6.89 Mn |
| Mar 31, 2025 | -6.89 Mn |
| Dec 31, 2024 | -1.07 Mn |
| Dec 31, 2024 | -1.07 Mn |
| Sep 30, 2024 | -4.00 Mn |
| Sep 30, 2024 | -4.00 Mn |
| Jun 30, 2024 | -1.10 Mn |
| Jun 30, 2024 | -1.10 Mn |
| Mar 31, 2024 | -4.96 Mn |
| Mar 31, 2024 | -4.96 Mn |
| Dec 31, 2023 | 124.49 Mn |
| Dec 31, 2023 | 124.49 Mn |